Jason Lettmann
Known title: DirectorCIK: 0001688269
Jason Lettmann's purchase track record
Jason Lettmann has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/16/2025 | ALXO | $99K | +32.4% | +100.9% | +1.7% |
| 3/14/2024 | ALXO | $50K | -24.3% | -80.8% | +8.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALXO | ▼ Sell | Open Market | 2,230 | $4K | 8/17/2026 | View on chart |
| ALXO | ▼ Sell | Open Market | 12,311 | $27K | 3/19/2026 | View on chart |
| ALXO | ▼ Sell | Tax Withholding | 2,201 | $5K | 2/17/2026 | View on chart |
| ALXO | ▲ Buy | Open Market | 71,163 | $77K | 9/17/2025 | View on chart |
| ALXO | ▲ Buy | Open Market | 21,070 | $22K | 9/16/2025 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,382 | $2K | 8/15/2025 | View on chart |
| ALXO | ▲ Buy | Grant | 42,000 | $0 | 3/14/2025 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,159 | $2K | 2/19/2025 | View on chart |
| ALXO | ▼ Sell | Tax Withholding | 2,191 | $6K | 8/14/2024 | View on chart |
| ALXO | ▲ Buy | Open Market | 4,400 | $50K | 3/14/2024 | View on chart |
| ALXO | ▲ Buy | Grant | 60,000 | $0 | 2/14/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 11,945 | $302K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,627 | $41K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 17,169 | $455K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,339 | $62K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 286,496 | $7.9M | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,296 | $36K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,196 | $62K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 299 | $8K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,329 | $39K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 181 | $5K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 440 | $13K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 60 | $2K | 12/13/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 967 | $30K | 12/10/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 15,942 | $503K | 12/10/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,172 | $69K | 12/10/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 88 | $3K | 12/10/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 12 | $386 | 12/10/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 7,093 | $218K | 12/10/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 11,452 | $356K | 12/9/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,560 | $48K | 12/9/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 42,203 | $1.4M | 12/9/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 5,751 | $184K | 12/9/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 14,028 | $459K | 12/9/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,911 | $63K | 12/9/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 35,836 | $1.2M | 12/8/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 4,883 | $162K | 12/8/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,531 | $52K | 12/8/2021 | View on chart |
| ALXO | ▼ Sell | Open Market | 208 | $7K | 12/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
ALX Oncology reports positive Phase 2 data for evorpacept
ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.
ALX Oncology reports positive Phase 2 data for evorpacept. ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.